ArchivesMagazine - 31 Aug 2017Creo’s Speedboat device approved in 49 days The medical device firm hopes to accelerate its US launch thanks to early approval 31 August 2017|Feature|by Lisa-Marie Janes Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Can Severfield continue to shine? Will Vectura update on key drug? > Issue: 31 Aug 2017 - Page 11 | Contents Next: Will Vectura update on key drug? Previous: Can Severfield continue to shine? Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Lisa-Marie Janes Issue Contents Editor's View Focus on sector data to get the investing edge Feature Real Good Food investors burned again UK bucks the rising dividend trend Cash accounts for nearly two thirds of news company’s market cap Best & Worst Performing FTSE 100 Stocks Sportech shareholders could win major cash prize Creo’s Speedboat device approved in 49 days Why the big moves in large cap share prices? Six ways to sharpen your investing skills CYBG could pay dividend after profit breakthrough Destiny to float on AIM and fight antibiotic resistance Funds Lifting the lid on the UK’s most popular funds Great Ideas Is Xafinity the ultimate defensive stock? Time to snap up WPP on price weakness Sopheon remains an exciting pick in the tech space Why GlaxoSmithKline is dominating the competition News When will developed economies be removed from life support? CentralNic’s Slovak profit boost Another bid for M.P. Evans? Economic impact of Hurricane Harvey Chemring can benefit from Trump’s Afghanistan push High hopes for imminent Appscatter IPO Computacenter comes good on cash return promise Personal Finance SIPPs versus personal pensions A brief guide to pensions and divorce Week Ahead IQE’s Apple link in focus Can Severfield continue to shine? Will Vectura update on key drug?
